亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台，協助業界發掘知識產權貿易商機，並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權，或是製造商需要購買技術以提高操作效能，又或是知識產權配套服務供應商，你將會從本網站發掘到有用的知識產權貿易資訊。

返回搜索結果

Diazene-Bridge Crown Ether Lithium Compounds And Methods For Their Use

總結: This Invention Provides A Method For Treating An Eye Disease In A Patient Comprising: Providing A Photosensitive Prodrug That Releases Upon Exposure To Light An Active Ingredient To Treat The Eye Disease; Administering The Prodrug In A Pharmaceutically Accepted Vehicle To The Subject, And Exposing The Eye Of The Subject To An External Light Source To Cause The Prodrug To Release The Active Ingredient. This Invention Also Provides A Composition For The Treatment Of Glaucoma, Comprising A Compound Containing A Lithium Ion-Chelated In A Crown Ether- Or Aza-Crown Ether-Containing Chromene Or Diazene Derivative And A Pharmaceutically Acceptable Carrier.

附加資料: Patent Number: US7468434B2
Application Number: US2005313513A
Inventor: Vanhoutte, Paul Michel Georges | Che, Chi-Ming | So, Kwok-Fai | Sham, Iona Hiu Tung
Priority Date: 22 Dec 2004
Priority Number: US7468434B2
Application Date: 21 Dec 2005
Publication Date: 23 Dec 2008
IPC Current: C07D022500
US Class: 540450 | 540467 | 540468 | 540469
Assignee Applicant: The University of Hong Kong
Title: Diazene-bridge crown ether lithium compounds and methods for their use
Usefulness: Diazene-bridge crown ether lithium compounds and methods for their use
Summary: For protecting degeneration of retinal ganglion cells in individual, where the degeneration is caused by eye disease e.g. glaucoma (claimed).
Novelty: Use of photosensitive prodrug that releases active ingredient upon exposure to light, for protecting degeneration of retinal ganglion cells in the treatment of eye disease e.g. glaucoma

欲了解更多信息，請點擊這裡